ABBV's $10.9B Apogee Acquisition Anchors Dividend Growth Outlook
What happened
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding a pipeline of antibody candidates targeting inflammatory and dermatological conditions. The deal is positioned to extend AbbVie's revenue diversification beyond Humira, which has faced biosimilar competition since 2023. AbbVie has raised its dividend for over 50 consecutive years, qualifying it as a Dividend King. Management has framed the Apogee transaction as a long-term growth lever for its immunology franchise.
The QL Read
With ABBV's composite signal at 59/100 and the stock down 0.73% on a mildly positive tape — 51.6% advancing — the pipeline thesis has yet to translate into near-term price action. Pipeline milestone updates and the next quarterly guidance print remain the near-term items to track.